Scientists have discovered the molecular switch that triggers innate immunity - body's first line of defence against pathogens.

While there are anti-viral drugs to treat influenza, the high rates of mutation that are characteristic of the influenza virus have made it difficult to treat with one universal drug or vaccine.
As for dengue, there are currently no clinically approved vaccines or cures either. This discovery of BTK's role as a critical 'switch' that boosts the body's anti-viral response, paves the way for developing anti-viral drugs that target the BTK 'switch' to fight infectious diseases.
To investigate the role of BTK in innate immunity, the research team from BTI extracted a class of innate immune cells known as macrophages from both normal mice and from mice deficient in BTK and challenged them with the dengue virus.
They found that the BTK-deficient immune cells were unable to produce interferons, and hence had much higher viral counts compared to the healthy immune cells that had high-levels of interferons to fight the virus effectively.
To further demonstrate the critical role of BTK in anti-viral response, the team focussed on BTK's role in Toll-like Receptor 3 (TLR3) signaling. TLR3 is needed for cells to activate the interferon response when cells are infected by viruses.
Advertisement
In contrast, a perpetually "off" BTK 'switch' led to a poor anti-viral response with very low levels of inteferons produced, and little protection against Dengue virus infection.
Advertisement
These patients do not have a functional BTK 'switch', and are unable to produce antibodies because defects in BTK cripple maturation of B cells, a type of white blood cell that produces antibodies.
"We are very excited because this is the first time that the link between BTK and its critical role in the immediate anti-viral responses of the immune system, triggered in response to invading viruses like Dengue, is definitively demonstrated," Koon-Guan Lee, first author of the paper, said.
Source-ANI